Treatment strategies that sensitize gemcitabine via inhibition of NPM1 oligomerization activity by NSC348884 can be further employed as a rational cancer therapy for CSN6‐high PDAC, especially in gemcitabine‐resistant patients. Here, NPM1 is linked to cancer.